Drug Search Results
More Filters [+]

UTAA-09

Alternative Names: UTAA-09, UTAA 09, UTAA09
Latest Update: 2024-07-16
Latest Update Note: Clinical Trial Update

Product Description

Off-the-shelf gamm delta T cells with a CD19-redirected Chimeric Antigen Receptor. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06092047)

Mechanisms of Action: CAR-T,CD19

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: PersonGen BioTherapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for UTAA-09

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Healthy Volunteers|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PG-CART-UTAA09-001

P1

Not yet recruiting

Oncology Unspecified|Healthy Volunteers

2026-07-01

Recent News Events

Date

Type

Title